Basic Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 8, 2017; 9(7): 368-384
Published online Mar 8, 2017. doi: 10.4254/wjh.v9.i7.368
Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2
Preeyanat Vongchan, Robert J Linhardt
Preeyanat Vongchan, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
Robert J Linhardt, Rensselaer Polytechnic Institute, Departments of Chemistry, Biology, Chemical and Biomedical Engineering, Troy, NY 12180, United States
Author contributions: Vongchan P (primary investigator) performed research, analyzed the data and prepared manuscript; Linhardt RJ contributed reagents and analytical tools, and revised manuscript.
Supported by National Research Council of Thailand (NRCT), No. 2559A10402115.
Institutional review board statement: Not available.
Institutional animal care and use committee statement: Not available.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest.
Data sharing statement: No additional are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Preeyanat Vongchan, PhD, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, 239 Huay Kaew Road, Muang District, Chiang Mai 50200, Thailand.
Telephone: +66-53-945080 Fax: +66-53-946042
Received: November 21, 2016
Peer-review started: November 23, 2016
First decision: December 15, 2016
Revised: December 19, 2016
Accepted: January 11, 2017
Article in press: January 14, 2017
Published online: March 8, 2017
Core Tip

Core tip: Heparan sulfate proteoglycan (HSPG) was isolated from human liver. Preliminary results showed that it was detected by rabbit anti-glypican. Monoclonal antibody, 1E4-1D9 was raised against human liver HSPG and its specific antigen was characterized. Amino acid sequence analysis revealed that the antigen recognized by mAb 1E4-1D9 specific molecule contained no transmembrane region. It has 15 cysteines and 11 putative glycosylation sites and 6 predicted N-glycosylation sites. The sequence matched to all PDZ domain proteins with an 85.6% match to glypican-3. Studies of co-expression and co-precipitation demonstrated that mAb 1E4-1D9 could compete with anti-glypican-3. It could also react with a various tumor cell lines including solid and hematopoietic cells. The findings suggested that the antigen recognized by 1E4-1D9 was glypican-3. Moreover, findings revealed that FYCO1 co-precipitated with glypican-3 using mAb 1E4-1D9, suggesting that FYCO1 is a partner molecule of glypican-3.